Explicyte earns ISO 13485 and ISO 9001 certifications for clinical tissue biomarker development & testing in oncology trials
Explicyte, a French precision oncology contract research organization (CRO), today announced that it has achieved ISO 13485:2016 and ISO 9001:2015 certifications for the design, development, and analysis of tissue-based clinical biomarkers to support precision oncology clinical trials. These certifications formalize Explicyte’s quality framework for delivering robust, reproducible, and traceable biomarker assays aligned with clinical-stage sponsor requirements. […]
A second Xenium: Explicyte doubles down on single-cell spatial transcriptomics
Bordeaux, France — December 3, 2025. A month after receiving the 10x Genomics’ « Certified Service Provider » designation across Xenium, Visium HD, and Chromium X, Explicyte, a French precision oncology contract research organization (CRO), today announced that it has doubled its capacity in single-cell spatial biology with the acquisition of a second Xenium platform. […]
Single-Cell Spatial Biology: Explicyte Becomes the First 10x Genomics-Certified Service Provider in France for Xenium studies
French CRO earns Xenium, Visium HD and Chromium X certification from 10x Genomics and deploys industrial-grade spatial biology platform to accelerate biomarker discovery & drug development in oncology, and beyond. Bordeaux, France — November 4, 2025. Explicyte, a French precision oncology contract research organization (CRO), today announced it has received 10x Genomics’ Certified Service Provider […]
Cure51 Partners with Explicyte for Spatial Analysis of Exceptional Cancer Survivor Samples from 40 Countries
Over the past two years, Cure51 has collected tumor samples from 1000 exceptional cancer survivors in collaboration with 100+ leading cancer centers worldwide. A first batch of tumor samples, processed and qualified at Institut Gustave Roussy in Paris, is being transferred in June 2025 to Explicyte—a Bordeaux-based CRO dedicated to precision oncology with unique capacities […]
Domain Therapeutics and Explicyte Enter Partnership Agreement in Immuno-Oncology
Strasbourg and Bordeaux, France — March 10, 2022 — Domain Therapeutics, a biopharmaceutical company specializing in the discovery and development of new drugs targeting G protein-coupled receptors in immuno-oncology, and Explicyte, a specialty immuno-oncology CRO with expertise in innovative target identification through multiparametric approaches, today announce the signing of a partnership agreement. Through this collaboration, […]
CONDOR Consortium Awarded RHU Funding to Advance Precision Medicine and Immunotherapy in Soft Tissue Sarcomas
The CONDOR consortium, led by Pr Antoine Italiano of Institut Bergonié in Bordeaux, has been selected as one of the 17 national awardees of the fifth call for Hospital-University Research in Health projects, known as RHU5. Selected from 89 submitted applications, this €30 million project will receive more than €9.8 million in funding to implement […]
Explicyte Becomes a Certified NanoString Partner to Advance Digital Spatial Profiling in Oncology
Explicyte is proud to announce its certification as a NanoString partner, reinforcing its commitment to bringing advanced spatial biology technologies to oncology and immuno-oncology research programs. With the increasing need to better understand tumor complexity and heterogeneity, spatially resolved technologies are becoming essential to investigate biological mechanisms directly within tissue compartments of interest, such as […]
Explicyte and Institut Bergonié Partner to Advance Translational Immuno-Oncology Research
Bordeaux, France — March 24, 2019 — Explicyte and Institut Bergonié have entered into a strategic collaboration to jointly drive a comprehensive translational research program focused on identifying mechanisms of resistance to immune checkpoint inhibitors in cancer patients. Addressing Resistance to Immune Checkpoint Inhibitors Over the last few years, cancer immunotherapies designed to mobilize the […]
Eurostars Grants MODIFY-NK Project to Develop a Novel Modified NK Cell Immunotherapy for Solid Tumours
Eurostars, a European joint programme co-funded by the national budgets of several EUREKA countries and by the European Union through Horizon 2020, has awarded funding to the project “A Novel Modified Natural Killer Cell Immunotherapy for the Treatment of Solid Tumours”, also known as MODIFY-NK. Selected through a highly competitive evaluation process, MODIFY-NK brings together […]